These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9246677)

  • 1. Antisense strategies in neurobiology.
    Weiss B; Davidkova G; Zhang SP
    Neurochem Int; 1997 Sep; 31(3):321-48. PubMed ID: 9246677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense strategies in dopamine receptor pharmacology.
    Weiss B; Zhang SP; Zhou LW
    Life Sci; 1997; 60(7):433-55. PubMed ID: 9042372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense RNA gene therapy for studying and modulating biological processes.
    Weiss B; Davidkova G; Zhou LW
    Cell Mol Life Sci; 1999 Mar; 55(3):334-58. PubMed ID: 10228554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antisense oligodeoxynucleotides directed to individual calmodulin gene transcripts on the proliferation and differentiation of PC12 cells.
    Hou WF; Zhang SP; Davidkova G; Nichols RA; Weiss B
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):295-308. PubMed ID: 9743467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrastriatal administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor mRNA inhibits D2 dopamine receptor-mediated behavior and D2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine.
    Zhou LW; Zhang SP; Weiss B
    Neurochem Int; 1996 Dec; 29(6):583-95. PubMed ID: 9113126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides in the study of central mechanisms of the cardiovascular regulation.
    Culman J
    Exp Physiol; 2000 Nov; 85(6):757-67. PubMed ID: 11187969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of a D2 dopamine receptor antisense RNA in brain inhibits D2-mediated behaviors.
    Weiss B; Davidkova G; Zhou LW; Zhang SP; Morabito M
    Neurochem Int; 1997 Oct; 31(4):571-80. PubMed ID: 9308007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated messenger RNA levels after antisense oligodeoxynucleotide treatment in vitro and in vivo.
    Probst JC; Skutella T
    Biochem Biophys Res Commun; 1996 Aug; 225(3):861-8. PubMed ID: 8780703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines.
    Raschellà G; Negroni A; Skorski T; Pucci S; Nieborowska-Skorska M; Romeo A; Calabretta B
    Cancer Res; 1992 Aug; 52(15):4221-6. PubMed ID: 1638535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense inhibition of the renin-angiotensin system in brain and peripheral organs.
    Mohuczy D; Phillips MI
    Methods; 2000 Nov; 22(3):197-209. PubMed ID: 11071815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense GAP-43 inhibits the evoked release of dopamine from PC12 cells.
    Ivins KJ; Neve KA; Feller DJ; Fidel SA; Neve RL
    J Neurochem; 1993 Feb; 60(2):626-33. PubMed ID: 8419540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems.
    Nicot A; Pfaff DW
    J Neurosci Methods; 1997 Jan; 71(1):45-53. PubMed ID: 9125374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotides fail to inhibit the expression of central beta adrenergic receptors.
    Zhang K; O'Donnell JM
    Res Commun Mol Pathol Pharmacol; 1997 Jan; 95(1):21-32. PubMed ID: 9055346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligodeoxynucleotides antisense to mRNA encoding protein kinase A, protein kinase C, and beta-adrenergic receptor kinase reveal distinctive cell-type-specific roles in agonist-induced desensitization.
    Shih M; Malbon CC
    Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12193-7. PubMed ID: 7991605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.
    Reed JC; Stein C; Subasinghe C; Haldar S; Croce CM; Yum S; Cohen J
    Cancer Res; 1990 Oct; 50(20):6565-70. PubMed ID: 2208117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligodeoxynucleotide and ribozyme design.
    Probst JC
    Methods; 2000 Nov; 22(3):271-81. PubMed ID: 11071823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes.
    Nash KL; Alexander GJ; Lever AM
    J Viral Hepat; 2005 Jul; 12(4):346-56. PubMed ID: 15985004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.